SEC Form 10-K filed by ADC Therapeutics SA
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $6.00 | Overweight | Stephens |
| 5/30/2024 | Overweight | Cantor Fitzgerald | |
| 3/28/2024 | $11.00 | Buy | Guggenheim |
| 8/10/2023 | Underweight → Neutral | JP Morgan | |
| 4/24/2023 | $7.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 12/6/2022 | $12.00 | Overweight | CapitalOne |
| 11/9/2022 | $14.00 → $7.00 | Buy → Neutral | BofA Securities |
| 9/21/2022 | $5.00 | Overweight | JP Morgan |
S-3 - ADC Therapeutics SA (0001771910) (Filer)
10-K - ADC Therapeutics SA (0001771910) (Filer)
8-K - ADC Therapeutics SA (0001771910) (Filer)
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you
LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares to three new employees on March 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motiva
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
4 - ADC Therapeutics SA (0001771910) (Issuer)
Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00
Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight
Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:
Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up Combination continues to be generally well-tolerated with a manageable safety profile LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at 8:00 a.m. EST LAUSANNE, Switzerland, Dec. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phas